Regular Evaluation for Corticotroph Tumor Progression Using Pituitary MRIs and ACTH Levels
STEP 1 — Gather Information
Collect history of bilateral adrenalectomy or presumed occult ectopic ACTH secretion, current serum ACTH level, pituitary MRI with sellar assessment, timing of last evaluation, and symptoms of hypercortisolism (weight gain, hypertension, hyperglycemia, hypokalemia, hyperpigmentation). Document baseline ACTH, pituitary MRI, symptoms, and timing of last evaluation.
STEP 2 — Rule In / Rule Out
If ACTH exceeds the upper limit of normal for the assay or MRI shows a new or enlarging pituitary lesion, rule in corticotroph tumor progression; if ACTH is stable or declining and MRI shows no change, rule out progression.
STEP 3 — Classify or Stratify
Classify as stable (ACTH unchanged, MRI unchanged), suspected progression (ACTH rising but MRI unchanged or equivocal), or confirmed progression (ACTH rising with concordant MRI lesion growth).
STEP 4 — Decide
If stable, schedule repeat evaluation in 6–12 months; if suspected, repeat ACTH and pituitary MRI in 3–6 months; if confirmed, discuss repeat transsphenoidal surgery, pituitary radiation, or medical therapy with the multidisciplinary team.
Clinical Guardrails / Mimics / Pitfalls
Do not rely solely on ACTH without correlating MRI, as postoperative ACTH elevation may reflect HPA axis recovery rather than tumor growth. Avoid delaying evaluation in symptomatic patients with hyperpigmentation or worsening cortisol excess. Do not mistake Nelson syndrome hyperpigmentation for tumor progression without imaging confirmation. Ensure off‑medication cortisol testing when interpreting ACTH trends.
Concrete Clinical Example
A 48‑year‑old woman with Cushing’s disease status post bilateral adrenalectomy 18 months prior presents with worsening fatigue and mild hyperpigmentation. ACTH is 210 pg/mL (baseline 70 pg/mL) and pituitary MRI reveals a 7 mm enhancing lesion not seen on prior scan. The team classifies this as confirmed progression and recommends repeat transsphenoidal surgery.
Source: Treatment of Cushing’s Syndrome: An Endocrine Society Clinical Practice Guideline, Nieman et al., Endocrine Society, 2015, DOI:10.1210/jc.2015-1818